【诺诚健华(09969.HK)：董事、高管合计减持31.875万股股份】智通财经APP讯，诺诚健华(09969.HK)公布，公司于近日收到执行董事、董事会主席、行政总裁 Jisong Cui(崔霁松)、执行董事、血液瘤医学研究和临床开发高级副总裁Renbin
Zhao(赵仁滨)和首席技术官XiangyangChen(陈向阳)出具的《关于股份减持结束的告知函》，截至本公告披露日，董事长崔霁松、执行董事赵仁滨、首席技术官陈向阳三人合计通过集中竞价减持 31.875 万股A股股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.